MID-Immuno 2015
♥ ‫أبو حديد‬
35/40 ‫العامة كانت‬
 
1.      
Selective immunosuppression
is included in it Artificial tolerance
Artificial tolerance

2.      
Can occur after taken
certain medications Self Modification
Modification
3.      
May speed up cell growth
and cell cycle for the cells that have it in active form Oncogenes
Oncogenes

4.      
Immune response to it leads
to autoimmune disease Autoantigen
Autoantigen

5.      
Some intracellular are
included in it. Pathogens
Pathogens

6.      
When the immune system is
weak it weakens and cancer ensues Immunosurveillance
Immunosurveillance

7.      
If it happens it could lead
to autoimmunity Self
DNAModification
damage
8.      
Apoptosis prevent cancer
caused by it.  DNA damage
DNA damage

9.      
Immunosuppressive drugs is
used to establish Artificial tolerance
Artificial tolerance

10.  
In absence of or weak
apoptosis could cause cancer DNA damage
DNA damage

11.  
A process that leads to
self modification Pathogens
DNA damage
12.  
Exposure to some of it can
cause cancer Pathogens
Pathogens

13.  
Its release lead to break
down of self tolerance Sequestered antigen
Sequestered antigen

14.  
Chronic exposure to it
leads to autoimmunity Pathogens
Pathogens

15.  
When its strong and well
regulated it prevents both cancer and some autoimmunity Immunosurveillance
Immunosurveillance

16.  
Responsible for cancer
associated antigen expression Oncogenes
Oncogenes

17.  
Positive and negative
selection are two processes that lead to it Natural tolerance
Natural tolerance

18.  
Suppression of immune
response to all self antigen is caused by it Natural tolerance
Natural tolerance

19.  
Could be active in fetus
normally and its reactivation in adult cause cancer. Oncogenes
Oncogenes

20.  
Its activation leads to
cancer  Oncogenes
Oncogenes

21.  
Its focus is a common
extracellular self molecule Systemic autoimmune
Systemic autoimmune diseases
diseases
 
22.  
Recipient is treated with
immunosuppressive drugs before it Transplantation
Transplantation
 
23.  
It is the focus of organ
specific autoimmunity Tissue specificantigen
Tissue specific antigen
 
24.  
It is a major risk factor
in autoimmunity Response
Genetic makeup
to self
 
25.  
It is not allowed if our
immune system is working properly Response
Response totoself
self

mid-2015.htm[5/24/2015 6:20:16 PM]

  
26.  
Its breakdown leads to
autoimmunity Self tolerance
tolerance
 
27.  
Always lead to autoimmunity
Response
Response totoself
self
 
28.  
Its failure leads to cancer
Immunosurveillance
Immunosurveillance
 
29.  
It interacts with the
environment to cause autoimmune diseases Genetic makeup
Genetic makeup
 
30.  
It can lead to multiorgan
failure if not treated Systemic autoimmune
Systemic autoimmune diseases
diseases
 
31.  
TSA is included in it Cancer
Cancer
 
32.  
Its failure leads to
enhanced graft survival Immunosurveillance
Tissue specific antigen
 
33.  
A process necessary to self
tolerance Recognition
Recognition ofof self
self
 
34.  
Suppresses autoreactive
clones Immune regulation
Immune regulation
 
35.  
Immunosuppressive drugs is
one of its treatment methods Systemic autoimmune
Systemic autoimmune diseases
diseases
 
36.  
It keeps the shapes of our
cells surface molecules under check Immunosurveillance
Immunosurveillance
 
37.  
Viruses is one of its
causative agents Cancer
Cancer
 
38.  
Its weakness in adult leads
to autoimmunity Immune regulation
Immune regulation
 
39.  
An abnormal condition that
does not occur in absence of T-lymphocytes Response
Response totoself
self
 
40.  
It is a process that does
not lead to autoimmunity Recognition
Recognition ofofself
self
 
41.  Passenger cells are involved in it GVHD
GVHD

42. 
A
graft from one individual to another in the same mouse strain. Allograft
Isograft

43. 
It
is done before grafting to eliminate or minimize host response to graft Tissue typing
Tissue typing

44. 
It
deletes autoreactive B lymphocytes in the lymph nods Peripheral Tolerance
Peripheral Tolerance

45. 
The
host immune response to the transplanted tissue Graft rejection
Graft rejection

46. 
It
protects from autoimmune disease and take place in primary lymphoid
Central tolerance
Central tolerance
organs
47. 
It
starts with lymphocytes tissue infiltration Inflammation
Graft rejection

48. 
Unmatched
bone marrow graft always do GVHD
GVHD

49. 
The
immune system is able to do against cancer Immune response
Immune response

mid-2015.htm[5/24/2015 6:20:16 PM]

 50. 
It
is only done to cellular noneself antigen by recipient immune system Immune
Graft response
rejection

51. 
Cause
by donor response to the recipient tissues GVHD
GVHD

52. 
It
is mainly done before birth Central tolerance
Central tolerance

53. 
It
deletes autoreactive T lymphocytes in the thymus Central tolerance
Central tolerance

54. 
No
eliminating immune response is mounted against Isograft
Isograft

55. 
It
does not happen in the primary lymphoid organs Peripheral Tolerance
Peripheral Tolerance

56. 
Mixed
lymphocytes reaction (MLR) is used in it Tissue typing
Tissue typing

57. 
A
graft from one individual to another in the same species Allograft
Allograft

58. 
Its
failure leads to severe autoimmune diseases Central tolerance
Central tolerance

59. 
A
graft between monozygotic twines. Isograft
Isograft

60. 
If
cancer is diagnosed the immune system failed to do Eliminating
Eliminating immune
immune response
response

61.  
It can be determined by the
use of monoclonal antibody’s. Immunoscintigraphy
Immunoscintigraphy
62.  
ADCC is part of it Immunological component
Immunological component of rejection
of rejection

63.  
It is a DNA based tissue
typing PCR
PCR

64.  
It is specific and its use
starts will before transplantation Selective immunosuppression
Selective immunosuppression

65.  
A second graft of it will
be rejected hyperacutely Xenograft
Xenograft

66.  
It is general and its use
starts will before transplantation Immunosuppressive drugs
Immunosuppressive drugs

67.  
It is used to diagnose
cancer Immunoscintigraphy
Mixed lymphocyte reaction (MLR)
68.  
The immune system will not
mount an immune response against Autograft
Autograft

69.  
Can be done serologically Tissue typing
Tissue typing

70.  
Cues general suppression of
the immune response Immunosuppressive drugs
Immunosuppressive drugs

71.  
The focus of the host
verses graft immune response HLA haplotype
HLA haplotype

72.  
Its matching enhances graft
acceptance HLA haplotype
HLA haplotype

73.  
Immunosuppressive drugs
will not do by themselves Selective
Xenograft immunosuppression
74.  
Complement is part of it Immunological component
Immunological component of rejection
of rejection

75.  
CMI is its dynamo Mixed lymphocyte
Mixed lymphocyte reaction
reaction (MLR)
(MLR)

76.  
Can be used for tissue
typing regardless of the donor PCR
Immunoscintigraphy
77.  
It is from the same species
and no need to tissue type it Autograft
Autograft

78.  
Cytokines are an integral
part of it Immunological component
Immunological component of rejection
of rejection

79.  
Radioactivity is always
used in it Immunoscintigraphy
Immunoscintigraphy
80.  
Can be used for both tissue
typing and testing immune response to cancer cells
Mixed lymphocyte
Mixed lymphocyte reaction
reaction (MLR)
(MLR)

mid-2015.htm[5/24/2015 6:20:16 PM]